Sat, Mar 17, 2018
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Greenwich Composite Investable Index gained 0.29% in August

Friday, October 01, 2010
Opalesque Industry Update - The Greenwich Composite Investable Index gained 0.29% in August in tumultuous market conditions, with returns from Arbitrage and Futures managers contributing the most to performance. 6 of 9 Greenwich Investable Indices moved higher on the month, as some strategy groups turned in their best performance so far this year.

The Greenwich Investable Futures Index was the best performer for the month, gaining 3.56% as trend-following strategies capitalized on moves in fixed income and commodities. The Greenwich Investable Arbitrage Index posted the second best results, advancing 1.86%. The Greenwich Long-Short Equity Investable Index declined by 28 basis points, a relatively strong performance given the monthly declines of 4.74% and 3.93% for the S&P 500 Total Return Index and MSCI World Equity Index.

Year-to-date, Fixed Income strategies still lead other Investable Indices, with Event-Driven, Long-Short Credit, and Arbitrage Investable Indices netting gains of 5.88%, 4.91%, and 6.71%, respectively.

“August was an excellent month for hedge funds across nearly every strategy. Long-Short Equity managers who remained skeptical of the market success maintained low net exposures and were quick to hedge market risk. As a result, while equity indices gave back the majority of the returns seen in July, Long-Short funds surrendered only a fraction of their previous gains.” noted Clint Binkley, Senior Vice President. “Other strategies saw outsized gains that were among their best results so far in 2010. Futures and Arbitrage managers, in particular found success through trend-following models and opportunities in the fixed income space.”

Website & performance table: Source

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Performance - Hedge fund mojo is back with investor hopes at six-year high, These hedge funds produce the most consistently great results[more]

    Hedge fund mojo is back with investor hopes at six-year high From Hedge funds on the heels of a surprisingly strong performance in 2017 are raising hopes for an encore. Investors expect their managers to return 8.5 percent in 2018, according to a Credit Suisse Group AG sur

  2. Investing - Hedge funds amass big bets against world's leading advertisers, Investor Elliott Management buys tiny stake in Wipro[more]

    Hedge funds amass big bets against world's leading advertisers From Hedge funds have amassed bearish bets of more than $3bn against the world's largest advertising companies in an attempt to profit as the industry undergoes ongoing wrenching disruption and slowing growth. Funds i

  3. News Briefs - Investcorp to launch a $100 million PE fund for Omani pension funds[more]

    Bahrain-based investment firm Investcorp will soon launch a $100 million fund dedicated to Oman's Pension Funds as part of its investment plan. 'The Opportunities Fund' will be focused on private equity investments in the U.S. and Europe and will target mid-sized companies across a broad range of se

  4. DoubleLine's Gundlach sees U.S. 10-year Treasury yield rising, weighing on stocks[more]

    From Reuters/ Jeffrey Gundlach, the chief executive of DoubleLine Capital and known on Wall Street as the "Bond King," said on Tuesday the yield on the U.S. 10-year Treasury note will likely move higher and pressure riskier assets including equities and junk bonds. Gundlach, on an

  5. SEC charges Theranos CEO Holmes with fraud[more]

    Bailey McCann, Opalesque New York: The SEC has charged Elizabeth Holmes, founder and CEO of Theranos and its former President Ramesh "Sunny" Balwani with raising more than $700 million from investors through an elaborate, years-long fraud in which they exaggerated or made false statements about t